Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cancer Research UK Phase I Trial of 4-(N-(S-Glutathionylacetyl) Amino) Phenylarsenoxide (GSAO) Given as Daily Intravenous Infusions on Days 1-5 and 8-12 of a 21-Day Cycle, to Patients With Advanced Solid Tumors

NCT01147029 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.

NCT NCT01147029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01147029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cancer Research UK Phase I Trial of 4-(N-(S-Glutathionylacetyl) Amino) Phenylarsenoxide (GSAO) Given as Daily Intravenous Infusions on Days 1-5 and 8-12 of a 21-Day Cycle, to Patients With Advanced Solid Tumors
Lead sponsor
Cancer Research UK
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2008
Completion date
April 30, 2012
Enrollment
35 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific